Estimating the public economic consequences of cardiovascular disease-attributable events and evolocumab treatment in Australia

References

• Pond R, Stephens C, Alpass F. How health affects retirement decisions: three pathways taken by middle-older aged New Zealanders. Ageing & Society. 2010;30(3):527–545.
   Web of Science ®Google Scholar
• McGeary KA. How do health shocks influence retirement decisions? Rev Econ Household. 2009;7(3):307–321.
   Web of Science ®Google Scholar
• Saastamoinen P, Laaksonen M, Kääriä S-M, et al. Pain and disability retirement: a prospective cohort study. Pain. 2012;153(3):526–531.
   PubMed Web of Science ®Google Scholar
• Zucchelli E, Jones AM, Rice N, et al. The effects of health shocks on labour market exits: evidence from the HILDA survey. Australian J Labour Econ. 2010;13:191–218.
   Google Scholar
• Meding B, Wrangsjö K, Burdorf A, et al. Disability pensions due to skin diseases: a cohort study in Swedish construction workers. Acta Derm Venereol. 2016;96(2):232–236.
   PubMed Web of Science ®Google Scholar
• García-Gómez P, Van Kippersluis H, O’Donnell O, et al. Long term and spillover effects of health shocks on employment and income. J Hum Resour. 2013;48(4):873–909.
   PubMed Web of Science ®Google Scholar
• Jiménez‐Martín S, Labeaga Vilaplana Prieto MJ, Vilaplana Prieto C. A sequential model of older workers’ labor force transitions after a health shock. Health Econ. 2006;15(9):1033–1054.
   PubMed Web of Science ®Google Scholar
• Zomer E, Kumar R, Tonkin A. PCSK9 inhibitors in Australia: a cost-effectiveness analysis. Heart, Lung Circ. 2017;26:S348.
   Google Scholar
• Kazi DS, Penko J, Coxson PG, et al. Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial. JAMA. 2017;318(8):748–750.
   PubMed Web of Science ®Google Scholar
• Pit SW, Shrestha R, Schofield D, et al. Partial and complete retirement due to ill-health among mature age Australians. Public Health. 2013;127(6):561–571.
   PubMed Web of Science ®Google Scholar
• Fonarow GC, van Hout B, Villa G, et al. Updated cost-effectiveness analysis of evolocumab in patients with very high-risk atherosclerotic cardiovascular disease. JAMA Cardiol. 2019;4(7):691–695.
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Keech AC, Pedersen TR, et al. Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2017;2(10):1069–1078.
   PubMed Web of Science ®Google Scholar
• Connolly MP, Kotsopoulos N, Postma MJ, et al. The fiscal consequences attributed to changes in morbidity and mortality linked to investments in health care: a government perspective analytic framework. Value Health. 2017;20(2):273–277.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722.
   PubMed Web of Science ®Google Scholar
• Flather M. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. The Lancet. 2010;376:1670–1681.
   PubMed Web of Science ®Google Scholar
• Wilson PW, D’Agostino R, Sr Bhatt DL, et al. An international model to predict recurrent cardiovascular disease. Am J Med. 2012;125(7):695–703.
   PubMed Web of Science ®Google Scholar
• Lindh M, Banefelt J, Fox KM, et al. Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: estimates from Swedish population-based register data. Eur Heart J Qual Care Clin Outcomes. 2019;5(3):225–232.
   PubMed Web of Science ®Google Scholar
• AIHW. General record of incidence of mortality (GRIM). Canberra (Australia): Australian Government; 2011.
   Google Scholar
• PBS. Review of statin therapies. Canberra (Australia): Australian Government; 2012.
   Google Scholar
• PBS. Medicine list. Canberra (Australia): Australian Government; 2019.
   Google Scholar
• Schofield D, Shrestha R, Percival R, et al. The personal and national costs of CVD: impacts on income, taxes, government support payments and GDP due to lost labour force participation. Int J Cardiol. 2013;166(1):68–71.
   PubMed Web of Science ®Google Scholar
• Li J. STINMOD + Overview. 2019. https://stinmod.canberra.edu.au/research/stinmodplus/model_doc/overview
   Google Scholar
• Australian Council of Social Services (ACOSS). The impact on households of tax cuts and lifting Newstart Allowance. 2019. https://www.acoss.org.au/wp-content/uploads/2019/04/Impact-of-tax-cuts-and-Newstart-increase-on-households_FINAL.pdf
   Google Scholar
• Li J, La HA, Sologon DM. Policy, demography, and market income volatility: what shaped income distribution and inequality in Australia between 2002 and 2016? Rev Income Wealth. 2020. DOI:https://doi.org/10.1111/roiw.12467
   Google Scholar
• CentreLink. Disability support pension. Canberra (Australia): Australian Government Services; 2020.
   Google Scholar
• Challenger. Super is delivering for people about to retire. Canberra (Australia): Challenger; 2019.
   Google Scholar
• ABoS. Household expenditure survey, Australia: summary of results, 2015-16. Canberra (Australia): Australian Bureau of Statistics ABS; 2017.
   Google Scholar
• PC. Goods and Services Tax. Economic Implications of an Ageing Australia: 2019.
   Google Scholar
• Pharmaceutical Benefits Advisory Committee. Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee. Canberra (Australia): PBAC; 2016. Available from: http://pbac.pbs.gov.au:8999/content/information/files/pbac-guidelines-version-5.pdf/
   Google Scholar
• WHO. Cardiovascular Diseases. 2017. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
   Google Scholar
• ABoS. National health survey: first results 2017-18. Canberra (Australia): Australian Bureau of Statistics ABS; 2018.
   Google Scholar
• AIHW. Health care expenditure on cardiovascular diseases 2008–09. Bruce (Australia): AIHW; 2014.
   Google Scholar
• Schofield DJ, Callander EJ, Shrestha RN, et al. Labour force participation and the influence of having CVD on income poverty of older workers. Int J Cardiol. 2012;156(1):80–83.
   PubMed Web of Science ®Google Scholar
• Schofield D, Passey M, Percival R, et al. Retiring early with cardiovascular disease-impact on individual’s financial assets. Int J Cardiol. 2011;146(1):125–126.
   PubMed Web of Science ®Google Scholar
• Black DC. Dame Carol Black’s review of the health of Britain’s working age population. Working for a healthier tomorrow. London (UK): London Crown; 2008.
   Google Scholar
• Schofield D, Kelly S, Shrestha R, et al. The long term financial impacts of CVD: living standards in retirement. Int J Cardiol. 2012;155(3):406–408.
   PubMed Web of Science ®Google Scholar
• Callander EJ, Schofield DJ. The risk of falling into poverty after developing heart disease: a survival analysis. BMC Public Health. 2016;16:570.
   PubMed Web of Science ®Google Scholar
• Sabatine MS. PCSK9 inhibitors: clinical evidence and implementation. Nat Rev Cardiol. 2019;16(3):155–165.
   PubMed Web of Science ®Google Scholar
• Strilchuk L, Fogacci F, Cicero AF. Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data. Expert Opin Drug Saf. 2019;18(7):611–621.
   PubMed Web of Science ®Google Scholar
• Stuckler D, Reeves A, Mckee M. Social and economic multipliers: what they are and why they are important for health policy in Europe. Scand J Public Health. 2017;45(18):17–21.
   PubMed Web of Science ®Google Scholar
• Auerbach AJ, Gokhale J, Kotlikoff LJ. Generational accounting: a meaningful way to evaluate fiscal policy. J Econ Persp. 1994;8(1):73–94.
   Web of Science ®Google Scholar